IKNA

NASDAQ

Ikena Oncology Inc.

SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)IPO2021

News25/Ratings5

Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degrading enzyme; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Latest news

25 items

265dSEC
Ikena Oncology Inc. filed SEC Form 8-K: Leadership Update, Other Events
8-K - ImageneBio, Inc. (0001835579) (Filer)
267dINSIDER
SEC Form 4 filed by Chief Executive Officer Yarema Kristin
4 - ImageneBio, Inc. (0001835579) (Issuer)
267dINSIDER
Director Orbimed Advisors Llc was granted 83,611 shares (SEC Form 4)
4 - ImageneBio, Inc. (0001835579) (Issuer)
267dSEC
Amendment: SEC Form SCHEDULE 13D/A filed by Ikena Oncology Inc.
SCHEDULE 13D/A - ImageneBio, Inc. (0001835579) (Subject)
267dINSIDER
Director Bonita David P converted options into 379 shares and bought $2,499,969 worth of shares (83,611 units at $29.90) (SEC Form 4)
4 - ImageneBio, Inc. (0001835579) (Issuer)
267dINSIDER
Director Stampacchia Otello converted options into 379 shares and bought $7,999,924 worth of shares (267,556 units at $29.90) (SEC Form 4)
4 - ImageneBio, Inc. (0001835579) (Issuer)
268dINSIDER
Chief Financial Officer Marango Jotin was granted 15,776 shares and covered exercise/tax liability with 4,630 shares (SEC Form 4)
4 - ImageneBio, Inc. (0001835579) (Issuer)
268dINSIDER
Principal Accounting Officer Butler Erin was granted 3,051 shares (SEC Form 4)
4 - ImageneBio, Inc. (0001835579) (Issuer)
268dINSIDER
SEC Form 3 filed by new insider Butler Erin
3 - ImageneBio, Inc. (0001835579) (Issuer)
268dINSIDER
SEC Form 3 filed by new insider Yarema Kristin
3 - ImageneBio, Inc. (0001835579) (Issuer)
268dSEC
Amendment: SEC Form SCHEDULE 13D/A filed by Ikena Oncology Inc.
SCHEDULE 13D/A - ImageneBio, Inc. (0001835579) (Subject)
268dSEC
Ikena Oncology Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Leadership Update, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure
8-K - ImageneBio, Inc. (0001835579) (Filer)
269dSEC
Amendment: SEC Form SCHEDULE 13D/A filed by Ikena Oncology Inc.
SCHEDULE 13D/A - ImageneBio, Inc. (0001835579) (Subject)
272dSEC
Ikena Oncology Inc. filed SEC Form 8-K: Regulation FD Disclosure
8-K - Ikena Oncology, Inc. (0001835579) (Filer)
272dPR
Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million
The combined company will operate under the name "ImageneBio, Inc." and will begin trading on Nasdaq under the ticker symbol "IMA" at market open on Monday, July 28, 2025 ImageneBio, Inc. will continue to drive the ongoing Phase 2b clinical trial of non-depleting anti-OX40 monoclonal antibody, IMG-007, in patients with moderate-to-severe atopic dermatitis Phase 2b topline readout for IMG-007 in atopic dermatitis expected in the fourth quarter of 2026 SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals ("Inmagene"), a clinical stage biotechnology company dedicated to developing disease-modifying treatments for immunological/autoimmune and inflamma
273dSEC
SEC Form 10-Q filed by Ikena Oncology Inc.
10-Q - Ikena Oncology, Inc. (0001835579) (Filer)
273dSEC
SEC Form 8-K filed by Ikena Oncology Inc.
8-K - Ikena Oncology, Inc. (0001835579) (Filer)
274dPR
Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company
BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA) ("Ikena") and Inmagene Biopharmaceuticals ("Inmagene") today announced the appointment of Kristin Yarema, Ph.D. as Chief Executive Officer of ImageneBio ("Imagene"), of the combined company after the anticipated closing. "We are thrilled to welcome Dr. Yarema to the team. Kristin is bringing expertise to the team that will push the company, and our lead program, IMG-007, towards significant milestones," commented David Bonita, an Ikena director and a continuing board member of the combined company. "Her experience as a public company CEO and commercial leadership are valuable additions to this team.
275dSEC
SEC Form 8-K filed by Ikena Oncology Inc.
8-K - Ikena Oncology, Inc. (0001835579) (Filer)
279dSEC
SEC Form D filed by Ikena Oncology Inc.
D - Ikena Oncology, Inc. (0001835579) (Filer)
281dSEC
SEC Form 8-K filed by Ikena Oncology Inc.
8-K - Ikena Oncology, Inc. (0001835579) (Filer)
282dSEC
SEC Form 8-K filed by Ikena Oncology Inc.
8-K - Ikena Oncology, Inc. (0001835579) (Filer)
282dPR
Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals
Combined Company to Trade on Nasdaq Under Ticker "IMA" Ikena Announces 1-for-12 Reverse Stock Split of Ikena Common Stock BOSTON and SAN DIEGO, July 15, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA) ("Ikena") today announced the results of the annual meeting of its stockholders held on July 15, 2025. At the annual meeting, Ikena's stockholders voted in favor of all proposals, including a proposal approving the previously announced merger with Inmagene Biopharmaceuticals ("Inmagene"). The merger proposal allows for the issuance of shares of Ikena's common stock both to the shareholders of Inmagene and to the investors of the financing concurrent to the merger. Following th
286dSEC
SEC Form 425 filed by Ikena Oncology Inc.
425 - Ikena Oncology, Inc. (0001835579) (Subject)
286dSEC
SEC Form 8-K filed by Ikena Oncology Inc.
8-K - Ikena Oncology, Inc. (0001835579) (Filer)